SCI Pharmtech Inc
TWSE:4119
SCI Pharmtech Inc
Total Liabilities
SCI Pharmtech Inc
Total Liabilities Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Total Liabilities | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
S
|
SCI Pharmtech Inc
TWSE:4119
|
Total Liabilities
NT$1.7B
|
CAGR 3-Years
26%
|
CAGR 5-Years
23%
|
CAGR 10-Years
6%
|
|
|
Y
|
YungShin Global Holding Corp
TWSE:3705
|
Total Liabilities
NT$5.8B
|
CAGR 3-Years
1%
|
CAGR 5-Years
-1%
|
CAGR 10-Years
8%
|
|
|
Formosa Laboratories Inc
TWSE:4746
|
Total Liabilities
NT$6.2B
|
CAGR 3-Years
10%
|
CAGR 5-Years
4%
|
CAGR 10-Years
9%
|
|
|
ScinoPharm Taiwan Ltd
TWSE:1789
|
Total Liabilities
NT$1.4B
|
CAGR 3-Years
6%
|
CAGR 5-Years
0%
|
CAGR 10-Years
-3%
|
|
|
Lotus Pharmaceutical Co Ltd
TWSE:1795
|
Total Liabilities
NT$18.9B
|
CAGR 3-Years
23%
|
CAGR 5-Years
13%
|
CAGR 10-Years
8%
|
|
|
Standard Chem & Pharm Co Ltd
TWSE:1720
|
Total Liabilities
NT$5.3B
|
CAGR 3-Years
-3%
|
CAGR 5-Years
11%
|
CAGR 10-Years
10%
|
|
SCI Pharmtech Inc
Glance View
SCI Pharmtech Corp. is engaged in the biotechnology and medical care industry. The company is headquartered in Taoyuan, Taoyuan. The company went IPO on 2002-08-12. The firm's main products include APIs, API intermediates and special and precision chemicals. The firm distributes its products in domestic market and to overseas markets, including Europe, the Americas, the rest areas of Asia and others
See Also
What is SCI Pharmtech Inc's Total Liabilities?
Total Liabilities
1.7B
TWD
Based on the financial report for Dec 31, 2024, SCI Pharmtech Inc's Total Liabilities amounts to 1.7B TWD.
What is SCI Pharmtech Inc's Total Liabilities growth rate?
Total Liabilities CAGR 10Y
6%
Over the last year, the Total Liabilities growth was 8%. The average annual Total Liabilities growth rates for SCI Pharmtech Inc have been 26% over the past three years , 23% over the past five years , and 6% over the past ten years .
You don't have any saved screeners yet